期刊文献+

水飞蓟宾脂质纳米粒的制备与鼠体内分布研究 被引量:11

Study on the preparation and bio-distribution of silybin lipid nanospheres
下载PDF
导出
摘要 目的:探索水飞蓟宾脂质纳米粒的制备工艺,同时考察其形态、大小及鼠体内分布。方法:采用薄膜乳化高压均质技术制备的水飞蓟宾脂质纳米粒,高效液相色谱法测定小鼠灌胃给药后血及肝、脾、肺、肾、脑、心、胃中的水飞蓟宾。结果:水飞蓟宾脂质纳米粒扫描电镜多呈圆形,光子相关光谱测得其平均粒径为148.9 nm,多分散性指数为0.17,体内分布研究结果表明,与市售制剂相比,脂质纳米粒可显著减少水飞蓟宾在胃中的滞留,增加其在血及肝中的分布,肝靶向指数为1.81。结论:本法所制脂质纳米粒口服给药后可增加水飞蓟宾的肝位蓄积,无疑有助于肝炎的临床治疗。 Objective: To prepare silybin lipid nanospheres(SLN) and to evaluate the properties of morphology, particle size and the silybin distribution in mice. Method: Silybin lipid nanospheres were prepared by thin film emulsion-high pressure homogenization technique. Concentrations of silybin in mice blood, liver, spleen, lung, kidney, brain, heart, stomach after oral administration were determined by high performance liquid chromatography. Result: Scanning electron mierograph showed that most of the SLN were spherical. The average diameter from photon correlation spectrometer was 148.9 nm with the polydispersity 0.17. Body distribution data indicated that SLN could increase the distribution of silybin in blood and liver, decrease the amount of silybin in stomach as compared with the preparation on market, and the drug targeting index (DTI) in liver was 1.81. Conclusion: SLN can increase the uptake of silybin in liver after oral administration, which must benefit the hepatitis treatment.
机构地区 江苏大学药学院
出处 《中国中药杂志》 CAS CSCD 北大核心 2005年第24期1912-1914,共3页 China Journal of Chinese Materia Medica
基金 江苏省自然科学基金(BK2002007) 江苏高校高新技术产业化项目(JH01-061)
关键词 水飞蓟宾 脂质纳米粒 体内分布 肝脏靶向性 制备方法 silybin lipid nanospheres bio-distribution liver targeting
  • 相关文献

参考文献11

二级参考文献20

  • 1胡桂,杨今祥,云国杏.无环鸟苷固体分散体的研究[J].中国医院药学杂志,1995,15(3):115-116. 被引量:6
  • 2[1]Dienstag JL,Schiff ER,Mitchell M,et al.Extended Lamivudine retreatment for chronic hepatitis B[J].Hepatology,1996,24(1):188
  • 3[2]Muller RH,Mader K,Gohla S.Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art[J].Eur J Pharm Biopharm,2000,50(1):161
  • 4[3]Hashida M,Nishikawa M,Takakura Y.Hepatic targeting of drugs and proteins by chemical modification[J].J Controlled Release,1995,36(1/2):99
  • 5[4]Muller RH,Mehnert W,Lucks JS.Solid lipid nanoparticles (SLN)- an alternative colloidal carrier system for controlled drug delivery [J].Eur J Pharm Biopharm,1995,41:62
  • 6[5]Muller RH,Maassen S,Schwarz C.Solid lipid nanoparticles(SLN) as potential carrier for human use: interaction with human granulocytes[J].J Control Release,1997,47:261
  • 7[6]Muller RH,Ruhl D,Runge S,et al.Mehnert W.Cytotoxicity of Solid lipid nanoparticles as a function of the lipid matrix and the surfactant [J].Pharm Res,1997,14:458
  • 8[7]Schearz C,Mehnert W,Lucks JS,et al.Solid lipid nanoparticles (SLN) for controlled drug delivery.ⅠProduction,charecterazation and sterilization[J].J Control Release,1994,30(1):83
  • 9Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, et al. Inhibitory Effects of Silibinin on Cytochrome P-450 Enzymes'in Human Liver Microsomes. Pharmacol Toxicol, 2000, 86(6) :250.
  • 10Wu J, Zern M A. Hepatic Stellate Cells: A Target for the Treatment of Liver Fibrosis. J Gastrcenterol, 2000, 35(9):665.

共引文献89

同被引文献216

引证文献11

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部